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Background — Myocardial Infarction (MI) was reportedly precipitated 
by acquired and inherited risk factors including the G/A and 4G/5G 
polymorphisms within the promoter of the Plasminogen Activator 
Inhibitor -1 (PAI-1) gene. Objective — to investigate the association 
between gene polymorphism of the PAI-1 and MI in Tunisian.
Methods — PAI-1 G/A was genotyped with polymerase chain 
reaction — restriction fragment length polymorphism (PCR-RFLP) 
while PAI-1 4G/5G promoter genotype was established by allele 
speci c polymerase chain reaction ampli cation of genomic DNA. 
This study was performed in 305 myocardial infarction patients and 
328 unrelated healthy controls. All subjects clinical features and 
PAI-1 and t-PA activity were tested.
Results — There were two polymorphisms within the promoter 
(a G/A single base substitution polymorphism at -844 bp upstream 
from the start of transcription and an insertion (5G)/deletion 
(4G) polymorphism at position — 675). Higher frequency of the 
4G allele (p < 0.001 ; O.R. = 1.929), but a lower frequency of the 
5G allele (p < 0.001 ; O.R. = 0.356), were seen in patients vs. 
controls. The frequencies of the -844G (p < 0.001 ; O.R. = 0.314) 
allele was lower than -844A allele (p < 0.001 ; O.R. = 4.076) 
in patients versus controls. Furthermore signi cant elevation in 
plasma PAI-1 levels (88.43 ± 52.85 ng/ml vs. 62.18 ± 39.31 ng/
ml ; p <0.05) was seen among patients.
Conclusion — This study indicates that the risk of MI was notably 
high in 4G carriers and A carriers with elevated plasma PAI-1, and 
were associated with reduced t-PA levels.
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In spite of important therapeutic advances during the last 20 years, 
coronary atherothrombotic complications are and will remain the 
 rst cause of death all over the world. Acute coronary syndromes 
(ACS) are unpredictable and can lead to sudden death before any 
medical treatment. The development of new strategies for the 
screening of patients susceptible to develop an ACS is thus of major 
interest.
We hypothesized that coronary artery disease, in its stable and 
unstable forms, is associated with modi cations of the concentrations 
of various circulating proteins (circulating proteome), which could 
be assessed using a new method for pre-treatment of plasma 
(equalization) before differential proteomic analysis.
Every step from blood sampling to the proteomic analysis (nature 
of the tubes used, centrifugation time and speed, conditions of 
storage etc.) was strictly standardized
Three groups of 30 patients were studied: non-ST elevation 
myocardial infarction (group 1), stable angina (group 2), 
angiographically normal coronary arteries without extra-coronary 
atherosclerosis (group 3). Five milliliters of plasma from each 
patient were equalized ; this methodology (ProteominerTM, 
Biorad) is based on a solid-phase ligand library of hexapeptides 
which provides a potential ligand for every protein in the biological 
sample, with a limited capacity of binding for abundant proteins, 
thus allowing enrichment in low abundance proteins/peptides. 
Various strategies of elution have been used in order to increase the 
number of peaks/spots detected by SELDI-TOF mass spectrometry 
and by 2D-electrophoresis, respectively. Several differential peaks 
are currently being identi ed.
The screening, prognostic and therapeutic values of the new 
biomarkers discovered using this novel approach will require 
further validation, using more straightforward assays (eg, ELISA) 
in case-control and prospective cohorts of patients with coronary 
artery disease.
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Background — Macrophages, key regulators of healing/regeneration 
processes, strongly in ltrate ischemic tissues from patients suffering 
from critical limb ischemia (CLI). However pro-in ammatory 
markers correlate with disease progression and risk of amputation, 
suggesting that modulating macrophage activation state might be 
bene cial. We previously reported that thrombospondin-1 (TSP-1) 
is highly expressed in ischemic tissues during CLI in humans. TSP-
1 is a matricellular protein that displays well-known angiostatic 
properties in cancer, and regulates in ammation in vivo and 
macrophages properties in vitro. We therefore sought to investigate 
its function in a mouse model of CLI.
Methods and  ndings — Using a genetic model of tsp-1-/- mice 
subjected to femoral artery excision, we report that tsp-1-/- 
